Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Trading 07-17 14:26:09

54.09

-1.90

-3.39%

High56.17	Low53.02	Vol104.54M
Open56.00	D1 Closing55.99	Amplitude5.63%
Mkt Cap359.00B	Tradable Cap345.04B	Total Shares6.64B
T/O5.66B	T/O Rate1.64%	Tradable Shares6.38B
P/B5.84	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":54.09,"timestamp":1784269569000,"preClose":55.99,"halted":0,"volume":104540049,"delay":0,"changeRate":-0.0339,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"Trading","change":-1.9,"latestTime":"07-17 14:26:09","open":56,"high":56.17,"low":53.02,"amount":5660000000,"amplitude":0.0563,"askPrice":54.1,"askSize":193,"bidPrice":54.07,"bidSize":29,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1784271600000},"marketStatusCode":2,"adr":0,"adjPreClose":55.99,"symbolType":"stock","openAndCloseTimeList":[[1784251800000,1784259000000],[1784264400000,1784271600000]],"highLimit":61.59,"lowLimit":50.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.84,"roa":"--","peRate":44.216464,"roe":"4.15%","epsLYR":1.19,"committee":-0.559792,"marketValue":359006000000,"turnoverRate":0.0164,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":55.3,"timestamp":1784269540005,"preClose":57.95,"halted":0,"volume":2793293,"delay":0,"premium":"-11.64"},"floatMarketCap":345040000000},"requestUrl":"/m/hq/s/600276/wiki","defaultTab":"wiki","newsList":[{"id":"2652476026","title":"Hengrui Pharma Gets China Clinical Trial Nod for Osteoarthritis Injection; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652476026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652476026?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:39","pubTimestamp":1784255983,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  received Phase 3 clinical trial approval from China's National Medical Products Administration for its HRS9531 injection, according to a Friday filing with the Shanghai bourse.Hengrui will initiate trials for the drug in obese adult patients with knee osteoarthritis.The HRS9531 injection targets the gastric inhibitory peptide receptor and glucagon-like peptide-1 receptor. It has been previously tested on type 2 diabetes, obesity with heart failure, sleep apnea, and polycystic ovary syndrome.The company's cumulative investment in the drug reached 700.8 million yuan.Shares fell 4% in Hong Kong and Shanghai during morning trading on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1997245094.SGD","LU2495084118.USD","LU0359201885.HKD","01276","LU2097828714.EUR","LU1580142542.USD","LU2148510915.USD","BK0196","LU1969619763.USD","BK1191","LU0359202008.SGD","LU2488822045.USD","LU2097828557.USD","BK0028","LU1820825898.SGD","LU1997244956.HKD","BK0188","LU2097828631.EUR","LU1064130708.USD","LU2543165471.USD","LU1655091616.SGD","LU0405327494.USD","LU1255011170.USD","LU1328615791.USD","LU2580892789.USD","BK0012","LU0405327148.USD","BK0183","LU1064131003.USD","LU2097828474.EUR","LU2580892862.HKD","LU0359201612.USD","BK0239","LU1146622755.USD","BK0060","LU1781817850.SGD","LU1997245177.USD","600276","LU2289578879.USD","LU2328871848.SGD","LU2097828805.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430491","title":"Chinese Drugmakers with Big Ambitions Struggle to Recruit Staff for Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651430491?lang=en_us&edition=fundamental","pubTime":"2026-07-16 07:00","pubTimestamp":1784156400,"startTime":"0","endTime":"0","summary":"ANALYSIS-Chinese drugmakers with big ambitions struggle to recruit staff for global expansionDrug development from Chinese companies has grown significantly over the past two decadesEfforts to expand ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nL6N42V0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU2097828557.USD","BK0028","HK0000320264.USD","LU1781817850.SGD","BK0183","LU1580142542.USD","LU2328871848.SGD","688185","BK0188","HK0000165453.HKD","LU2289578879.USD","LU2580892862.HKD","HK0000306685.HKD","LU1969619763.USD","BK1230","LU1655091616.SGD","LU2097828805.USD","LU2097828474.EUR","LU0405327148.USD","LU1255011170.USD","LU1997244956.HKD","BK0012","BK0060","LU0405327494.USD","LU1997245177.USD","BK0239","02696","HK0000320223.HKD","LU2580892789.USD","BK0196","LU2488822045.USD","LU2148510915.USD","00656","LU1997245094.SGD","LU1064130708.USD","600276","LU1328615791.USD","LU2097828631.EUR","LU1064131003.USD","LU2495084118.USD","LU1146622755.USD","BK1161","LU2097828714.EUR","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141347429","title":"Hengrui Pharma's HRS-8797 Tablet Receives Clinical Trial Approval Notification","url":"https://stock-news.laohu8.com/highlight/detail?id=1141347429","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141347429?lang=en_us&edition=fundamental","pubTime":"2026-07-15 16:52","pubTimestamp":1784105539,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (ASX: 600276) has announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notification from...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","LU2488822045.USD","LU1064131003.USD","BK1191","IBBQ","LU1997245177.USD","LU1023057109.AUD","LU2097828557.USD","LU1064130708.USD","LU2495084118.USD","BMED","LU2097828714.EUR","LU0359201885.HKD","LU1328615791.USD","LU1969619763.USD","LU2097828631.EUR","LU2148510915.USD","LU2289578879.USD","LU2328871848.SGD","LU2580892789.USD","LU2097828805.USD","BK0060","LU1997245094.SGD","LU0405327148.USD","LU0359201612.USD","LU2543165471.USD","LU2580892862.HKD","LU1580142542.USD","LU2097828474.EUR","01276","LU1655091616.SGD","LU1997244956.HKD","LU1255011170.USD","LU1820825898.SGD","BK0196","BK0183","BK0028","600276","BK0012","BK0239","LU0359202008.SGD","LU1781817850.SGD","LU0405327494.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122105956","title":"Mingyu Pharma, Led by Hengrui Veteran, Files for Hong Kong IPO Amid Fierce Market Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=1122105956","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122105956?lang=en_us&edition=fundamental","pubTime":"2026-07-15 07:21","pubTimestamp":1784071286,"startTime":"0","endTime":"0","summary":"Mingyu Pharmaceutical Co., Ltd. has recently submitted a listing application to the Hong Kong Stock Exchange, seeking to go public under Chapter 18A rules.As the domestic innovative drug sector...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0183","BK0028","LU2580892789.USD","BK0239","LU1146622755.USD","600276","LU2289578879.USD","LU2097828805.USD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","IPOS","LU1997245177.USD","KCAI","BK1191","LU1255011170.USD","FRHC","BK0012","BK1574","LU0405327148.USD","LU2543165471.USD","LU2580892862.HKD","KCE","01477","LU1820825898.SGD","LU0359201885.HKD","LU2097828557.USD","LU1997244956.HKD","LU2097828714.EUR","LU2097828631.EUR","LU1655091616.SGD","LU2097828474.EUR","LU2488822045.USD","LU0359202008.SGD","LU0405327494.USD","LU1580142542.USD","LU1781817850.SGD","BK4127","LU0359201612.USD","LU1328615791.USD","LU1064131003.USD","VXUS","LU1064130708.USD","BK0196","BK4585","LU1023057109.AUD","01276","LU2148510915.USD","BK0188","BK4588","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651123405","title":"Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2651123405","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651123405?lang=en_us&edition=fundamental","pubTime":"2026-07-14 09:44","pubTimestamp":1783993486,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  has secured clearance from China's drug regulator to begin clinical trials for its SHR-3079 injection to treat adult systemic lupus erythematosus and adult rheumatoid arthritis.There are currently no similar drugs approved for marketing globally, the company said in a Shanghai bourse filing on Tuesday.The drug is also already in Phase I trials for B-cell non-Hodgkin's lymphoma.Hengrui has invested about 24.4 million yuan in the project to date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1781817850.SGD","LU1255011170.USD","LU1064131003.USD","01276","LU1997244956.HKD","LU1997245177.USD","LU2097828631.EUR","LU2097828805.USD","LU1969619763.USD","LU2097828474.EUR","LU2580892862.HKD","LU2495084118.USD","BK0028","LU2328871848.SGD","BK0239","LU0359201885.HKD","600276","LU1146622755.USD","BK0012","LU0405327148.USD","LU1328615791.USD","LU2543165471.USD","LU1064130708.USD","LU1580142542.USD","BK0060","BK0196","LU0405327494.USD","BK0183","BK1191","LU2097828714.EUR","LU2289578879.USD","LU0359202008.SGD","LU2148510915.USD","LU2488822045.USD","LU1820825898.SGD","BK0188","LU0359201612.USD","LU1655091616.SGD","LU2097828557.USD","LU2580892789.USD","LU1997245094.SGD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193790873","title":"Hengrui Pharma's HRS-7058 Capsule Designated as Breakthrough Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1193790873","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193790873?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:35","pubTimestamp":1783946145,"startTime":"0","endTime":"0","summary":"The pharmaceutical company HENGRUI PHARMA (01276) has announced that its HRS-7058 capsule has been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1580142542.USD","LU1997244956.HKD","BK0060","BK1191","BK0028","BK0183","LU1255011170.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2097828631.EUR","BK0196","01276","LU1781817850.SGD","LU1997245094.SGD","LU2488822045.USD","LU2580892789.USD","LU0359202008.SGD","LU2543165471.USD","LU1820825898.SGD","BK0012","LU1997245177.USD","LU1328615791.USD","LU1023057109.AUD","LU0359201612.USD","LU2097828474.EUR","LU1064131003.USD","LU0405327494.USD","LU2328871848.SGD","LU0359201885.HKD","LU1146622755.USD","LU0405327148.USD","LU2097828557.USD","LU1655091616.SGD","LU2289578879.USD","LU2097828714.EUR","LU1969619763.USD","BK0188","BK0239","LU1064130708.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155705795","title":"Hengrui Pharma's FXI Antibody SHR-2004 Unveils Pivotal Phase III Data at ISTH 2026 LBA Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1155705795","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155705795?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:20","pubTimestamp":1783938057,"startTime":"0","endTime":"0","summary":"At the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress held in Paris from July 11th to 15th, significant positive results from the confirmatory Phase III study of Hengrui...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU2097828714.EUR","LU2328871848.SGD","LU2289578879.USD","LU1997245094.SGD","LU2097828474.EUR","LU2097828631.EUR","LU2580892789.USD","BK0196","LU0405327494.USD","BK1191","BK0239","LU2495084118.USD","LU1997245177.USD","BK0012","LU0359201612.USD","LU1997244956.HKD","LU0359202008.SGD","BK0028","LU1328615791.USD","LU1969619763.USD","LU2148510915.USD","BK0188","LU2543165471.USD","LU1781817850.SGD","LU2097828557.USD","LU1023057109.AUD","LU0359201885.HKD","LU1255011170.USD","III","LU1146622755.USD","LU1064131003.USD","LU2580892862.HKD","LU1580142542.USD","LU2488822045.USD","LU1655091616.SGD","BK4134","BK0183","BK0060","600276","LU2097828805.USD","LU1064130708.USD","01276","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650131443","title":"Elevar-hengrui Hit with Third FDA Rejection for Liver Cancer Therapy over Manufacturing Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2650131443","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650131443?lang=en_us&edition=fundamental","pubTime":"2026-07-11 01:06","pubTimestamp":1783703208,"startTime":"0","endTime":"0","summary":"UPDATE 2-Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concernsAdds background in paragraphs 2, 4, details throughoutJuly 10 (Reuters)-Elevar Therapeutics and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL4N43C18C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","LU2488822045.USD","BK0188","LU2097828714.EUR","BK0183","LU1255011170.USD","BK0012","LU1997245094.SGD","LU0405327148.USD","BK0196","LU2097828805.USD","LU1580142542.USD","LU2580892862.HKD","LU2097828474.EUR","LU0405327494.USD","LU2495084118.USD","LU1064131003.USD","LU1064130708.USD","BK0239","BK0028","LU2289578879.USD","LU2097828557.USD","LU1328615791.USD","LU2328871848.SGD","LU2097828631.EUR","LU1146622755.USD","LU1781817850.SGD","LU1969619763.USD","LU1655091616.SGD","LU2580892789.USD","LU1997245177.USD","LU1820825898.SGD","LU2148510915.USD","600276","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126339858","title":"Hengrui Pharma's Key Drug Iohexol Injection Added to National Essential Medicines List","url":"https://stock-news.laohu8.com/highlight/detail?id=1126339858","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126339858?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:10","pubTimestamp":1783685415,"startTime":"0","endTime":"0","summary":"Hengrui Pharma (HKG: 01276) has announced that its major product, Iohexol Injection, has been newly included in the National Essential Medicines List (2026 Edition).This inclusion follows a joint...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU1997244956.HKD","LU0359201885.HKD","BK0239","BK0188","BK0028","LU2495084118.USD","LU1146622755.USD","LU1255011170.USD","LU2580892862.HKD","LU2289578879.USD","LU0405327148.USD","LU2097828474.EUR","LU2097828557.USD","LU2543165471.USD","BK0196","LU1781817850.SGD","LU1064130708.USD","LU1820825898.SGD","LU1997245094.SGD","LU1064131003.USD","LU2097828805.USD","600276","LU2580892789.USD","LU0359202008.SGD","LU0405327494.USD","BK1191","LU1969619763.USD","BK0012","LU2148510915.USD","LU1997245177.USD","LU1023057109.AUD","LU1580142542.USD","LU1655091616.SGD","LU2097828714.EUR","LU2328871848.SGD","LU2488822045.USD","BK0183","LU1328615791.USD","01276","LU2097828631.EUR","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164726612","title":"Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1164726612","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164726612?lang=en_us&edition=fundamental","pubTime":"2026-07-10 15:04","pubTimestamp":1783667082,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA) has announced that it recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU1820825898.SGD","LU1655091616.SGD","LU0359202008.SGD","LU2495084118.USD","LU1997245177.USD","LU2580892789.USD","01276","LU1255011170.USD","LU1997245094.SGD","LU1969619763.USD","LU1023057109.AUD","LU1997244956.HKD","BK0028","LU1328615791.USD","LU1064131003.USD","LU2328871848.SGD","LU1146622755.USD","LU0405327148.USD","LU2097828474.EUR","LU1064130708.USD","LU1580142542.USD","LU2148510915.USD","BK0060","BK1191","LU1781817850.SGD","LU2289578879.USD","LU0359201612.USD","LU2488822045.USD","600276","LU2097828714.EUR","LU2543165471.USD","LU2580892862.HKD","LU0405327494.USD","BK0012","BK0239","LU2097828557.USD","LU2097828631.EUR","BK0183","LU0359201885.HKD","LU2097828805.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133734652","title":"UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=1133734652","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133734652?lang=en_us&edition=fundamental","pubTime":"2026-07-09 17:20","pubTimestamp":1783588834,"startTime":"0","endTime":"0","summary":"UBS has issued a research report highlighting positive clinical data for Hengrui Pharma (HKG: 01276)'s weight-loss drug candidate HRS-7535. The Phase III clinical trial for the drug has successfully...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201885.HKD","BK0060","BK0183","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD","LU1580142542.USD","LU1328615791.USD","LU1655091616.SGD","BK0012","BK1191","LU2097828557.USD","LU0405327494.USD","BK0188","01276","BK0028","LU1969619763.USD","LU1023057109.AUD","LU1820825898.SGD","LU1781817850.SGD","LU1064131003.USD","600276","BK0239","LU2488822045.USD","LU2097828631.EUR","LU0359202008.SGD","LU0359201612.USD","BK0196","LU1997244956.HKD","LU1997245094.SGD","LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","LU1255011170.USD","LU2097828714.EUR","LU1146622755.USD","LU2289578879.USD","LU0405327148.USD","LU2543165471.USD","LU2495084118.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649162984","title":"Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2649162984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649162984?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:21","pubTimestamp":1783423300,"startTime":"0","endTime":"0","summary":"UPDATE 3-Kailera shares tumble on high nausea rates despite weight-loss drug's successJuly 7 (Reuters)-Kailera Therapeutics'KLRA.Oshares dropped 10% on Tuesday after its oral weight-loss drug showed h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4390VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","03165","LU1989771016.USD","LU0405327494.USD","LU0526926950.USD","600276","LU1267930813.SGD","LU0889566641.SGD","BK0188","LU2237443549.SGD","LU2097828557.USD","LU0957799991.USD","LU1146622755.USD","LU2237443622.USD","LU2237443978.SGD","LU2097828805.USD","LU0203345920.USD","LU0310799852.SGD","LU1328615791.USD","LU2089284900.SGD","LU1078025761.USD","LU0345777659.USD","LU0310800965.SGD","LU1481600234.SGD","LU0266013472.USD","LU2293690249.USD","LU0784384876.USD","LU0972486137.USD","LU1267930227.SGD","SG9999001176.USD","LU1781817850.SGD","SGXZ57979304.SGD","LU0949170426.SGD","LU1273509221.SGD","LU0289739699.SGD","LU0496365809.HKD","LU2324357040.USD","LU1880407215.USD","LU0976567544.SGD","LU0211326839.USD","IE00B4R5TH58.HKD","LU2097828631.EUR","IE0034235188.USD","LU1064130708.USD","LU0960981461.USD","LU1046234339.USD","OZEM","LU0171276677.USD","AZN.UK","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648632449","title":"Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2648632449","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648632449?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:43","pubTimestamp":1783043039,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals , through its subsidiaries, received approval from China's National Medical Products Administration for the clinical trials of a drug combination for the treatment of hepatocellular carcinoma, according to a Shanghai bourse filing on Friday.The pharmaceutical company was given the green light to trial SHR-8068 injection in combination with adebelimab injection, and apatinib mesylate tablets.Adebelimab injection was already approved as a lung cancer treatment, while apatinib mesylate tablets was approved as a treatment for various cancers, including gastric, hepatocellular and breast cancer.The company's Hong Kong shares rose 2% and Shanghai shares increased 1% during the morning trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU2328871848.SGD","LU0359201612.USD","LU2097828557.USD","LU2097828805.USD","LU0405327494.USD","BK0196","LU0359201885.HKD","BK0028","LU1255011170.USD","LU2148510915.USD","LU1969619763.USD","LU2495084118.USD","LU1146622755.USD","LU1328615791.USD","BK0188","LU1997244956.HKD","BK0012","600276","01276","LU2580892789.USD","LU2543165471.USD","LU2097828631.EUR","LU2488822045.USD","LU1997245094.SGD","LU1820825898.SGD","LU2097828474.EUR","LU1064130708.USD","LU2289578879.USD","LU0405327148.USD","LU1655091616.SGD","LU1781817850.SGD","BK0239","LU1023057109.AUD","BK0060","LU2097828714.EUR","LU0359202008.SGD","LU1064131003.USD","LU1580142542.USD","LU1997245177.USD","LU2580892862.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180673816","title":"Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1180673816","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180673816?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:41","pubTimestamp":1782992511,"startTime":"0","endTime":"0","summary":"Hengrui Pharma has provided an update on its progress regarding the repurchase of its A-shares.During the month of June 2026, the company repurchased 1.414 million shares through the Shanghai Stock...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","LU1997245094.SGD","LU0405327148.USD","BK0012","LU1655091616.SGD","LU1255011170.USD","BK0028","01276","LU1580142542.USD","LU0359202008.SGD","LU0359201885.HKD","LU1820825898.SGD","LU2488822045.USD","600276","LU1997245177.USD","LU2580892789.USD","BK0239","LU2495084118.USD","LU1328615791.USD","BK0188","LU2097828631.EUR","LU1064131003.USD","LU2097828474.EUR","LU1781817850.SGD","LU2148510915.USD","LU2328871848.SGD","LU1146622755.USD","LU0405327494.USD","LU2543165471.USD","159982","LU2097828714.EUR","LU0359201612.USD","BK1191","LU1064130708.USD","399300","LU2289578879.USD","LU1969619763.USD","LU2580892862.HKD","LU2097828557.USD","BK0060","LU1023057109.AUD","BK0183","BK0196","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130917404","title":"Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=1130917404","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130917404?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:16","pubTimestamp":1782983789,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHSE: 600276) has announced that it, along with its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd.,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","LU1820825898.SGD","LU1969619763.USD","LU2328871848.SGD","LU2543165471.USD","LU2488822045.USD","LU0359202008.SGD","LU2097828557.USD","LU1580142542.USD","LU0405327494.USD","LU2580892862.HKD","LU2097828714.EUR","BK0060","LU1064130708.USD","LU2097828805.USD","BK0239","LU1997245094.SGD","BK0188","LU1997244956.HKD","BK0196","BK0183","LU0405327148.USD","LU0359201612.USD","LU2495084118.USD","LU1997245177.USD","LU1328615791.USD","LU1655091616.SGD","LU1064131003.USD","LU1781817850.SGD","LU2097828631.EUR","LU0359201885.HKD","LU2097828474.EUR","01276","LU2289578879.USD","LU2580892789.USD","LU1146622755.USD","LU1023057109.AUD","LU2148510915.USD","LU1255011170.USD","BK0012","BK1191","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162514605","title":"Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1162514605","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162514605?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:32","pubTimestamp":1782959548,"startTime":"0","endTime":"0","summary":"Shares of Hengrui Pharma (ASX: 01276) surged more than 6% during the trading session. At the time of writing, the stock was up 3.54% to HKD 59.9, with a turnover of HKD 136 million.The recent price...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","BK0012","BK0028","BK1161","LU0359202008.SGD","LU1997245177.USD","LU2097828557.USD","LU2580892862.HKD","01276","LU2488822045.USD","LU1997244956.HKD","LU2097828714.EUR","BK4588","LU1255011170.USD","BK1574","LU1023057109.AUD","06978","LU2097828631.EUR","LU2097828805.USD","BK0183","LU2148510915.USD","LU2495084118.USD","BK4585","LU1580142542.USD","159992","LU1781817850.SGD","LU2580892789.USD","LU1997245094.SGD","LU0359201885.HKD","LU1146622755.USD","600276","LU2328871848.SGD","BK0188","LU1064131003.USD","LU1655091616.SGD","BK1191","VXUS","BK0060","LU0359201612.USD","LU1064130708.USD","LU2543165471.USD","BK0239","LU0405327494.USD","LU1969619763.USD","LU2097828474.EUR","LU2289578879.USD","LU1820825898.SGD","BK0196","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647584173","title":"Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2647584173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647584173?lang=en_us&edition=fundamental","pubTime":"2026-06-30 13:00","pubTimestamp":1782795600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUAKW0NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2289578879.USD","LU0405327494.USD","600276","LU2580892862.HKD","BK0188","LU2097828557.USD","LU1146622755.USD","BK0012","LU0405327148.USD","LU2148510915.USD","LU2097828805.USD","LU1328615791.USD","BK0183","LU1064131003.USD","LU2097828474.EUR","BK0028","LU2097828714.EUR","LU1997244956.HKD","LU1997245094.SGD","LU2580892789.USD","LU1781817850.SGD","BK0060","BK0196","BK0239","LU2328871848.SGD","LU2488822045.USD","LU2097828631.EUR","LU1064130708.USD","LU1580142542.USD","LU2495084118.USD","LU1655091616.SGD","LU1255011170.USD","LU1997245177.USD","LU1820825898.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647327725","title":"Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2647327725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647327725?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:33","pubTimestamp":1782725580,"startTime":"0","endTime":"0","summary":"Chinese biopharma stocks rallied on Monday, as investors moved away from artificial-intelligence stocks amid concerns over overstretched valuations.Shares of BeOne Medicines led gains among biopharma ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK1161","CHAT","LU1008478684.HKD","86618","01093","BK1189","LU0140636845.USD","ONC","688180","BK0012","BK1571","BK1191","ISBC","XBI","ARTY","LABU","LU0405327494.USD","00241","BK4137","BK0028","02315","01877","LU1303224171.USD","603259","AIPO","BK1502","600276","BK0239","BK1583","BK0216","06618","LU2039709279.SGD","BK0196","LU1807302812.USD","01801","LU1251922891.USD","LU2328871848.SGD","LU1255011170.USD","LU1808992512.USD","IE00BPRC5H50.USD","09637","LU0456827905.SGD","AGIX","BK4585","HCSG","IE00BZ08YS42.EUR","LU0315179316.USD","LU1993786604.SGD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646336393","title":"Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646336393","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646336393?lang=en_us&edition=fundamental","pubTime":"2026-06-26 11:10","pubTimestamp":1782443414,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  received approval from China's National Medical Products Administration to conduct clinical trials on HRS-4508 tablets, according to a Shanghai bourse filing on Friday.The drug will be tested as a treatment for advanced solid tumors.The pharmaceutical company invested 81.8 million yuan into the research and development of the drug.The company's Hong Kong shares dropped 4%, while Shanghai shares slipped 1% during the morning trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2097828714.EUR","IE0031619046.USD","LU1023057109.AUD","LU1255011170.USD","LU2488822045.USD","BK0196","BK0012","LU1064130708.USD","LU2543165471.USD","LU2097828805.USD","IE00B7SZL793.SGD","LU1820825898.SGD","BK0188","LU2289578879.USD","LU0359201885.HKD","LU2097828631.EUR","BK4157","BK0060","BK0183","BK1191","IE00B66KJ199.SGD","LU1781817850.SGD","LU2328871848.SGD","LU1969619763.USD","BK0028","LU0757428866.USD","LU2097828557.USD","LU2495084118.USD","LU1997245177.USD","LU0359201612.USD","LU0405327148.USD","LU0359202008.SGD","LU1146622755.USD","LU1997245094.SGD","LU2580892789.USD","LU1580142542.USD","LU2580892862.HKD","LU2097828474.EUR","BK0239","LU1328615791.USD","LU0405327494.USD","LU1815336091.USD","LU1064131003.USD","600276","AEIS","IE00B19Z4B17.USD","LU1655091616.SGD","LU1997244956.HKD","LU2148510915.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137621027","title":"Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1137621027","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137621027?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:59","pubTimestamp":1782392348,"startTime":"0","endTime":"0","summary":"Hengrui Pharma has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently received notification from the National Medical Products Administration. The notification...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU2097828714.EUR","LU2328871848.SGD","LU2289578879.USD","LU1997245094.SGD","LU2097828474.EUR","LU2097828631.EUR","LU2580892789.USD","BK0196","LU0405327494.USD","BK1191","BK0239","LU2495084118.USD","LU1997245177.USD","BK0012","LU0359201612.USD","LU1997244956.HKD","LU0359202008.SGD","BK0028","LU1328615791.USD","LU1969619763.USD","LU2148510915.USD","BK0188","LU2543165471.USD","LU1781817850.SGD","LU2097828557.USD","LU1023057109.AUD","LU0359201885.HKD","LU1255011170.USD","LU1146622755.USD","LU1064131003.USD","LU2580892862.HKD","LU1580142542.USD","LU2488822045.USD","LU1655091616.SGD","BK0183","BK0060","600276","LU2097828805.USD","LU1064130708.USD","01276","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784269570420,"stockEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":0.1825},{"period":"3month","weight":-0.002},{"period":"6month","weight":-0.0924},{"period":"1year","weight":-0.0175},{"period":"ytd","weight":-0.0562}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.0417},{"period":"6month","weight":-0.0535},{"period":"1year","weight":0.1081},{"period":"ytd","weight":-0.0218}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction